People · Operator
Named in public records as an officer, director or promoter · active 2015–2015 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Xalud Therapeutics, Inc. | — | Biotechnology | Series B | $30.5M | $495.1M | 2015 |
John Forsayeth at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside John Forsayeth on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Paul B. Manning | 1 | 6 |
| Stephen Collins | 1 | 5 |
| Sean Stalfort | 1 | 5 |
| Diem B. Nguyen | 1 | 2 |
| Jayson Rieger | 1 | 2 |
| Raymond Chavez | 1 | 1 |
| Linda Watkins | 1 | 1 |
| Peter Heinecke | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.